SONN - Sonnet BioTherapeutics Holdings, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Princeton,
United States
Type: Equity
SONN price evolution
SONN
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3.79 | $3.02 | $2.27 | $7.02 |
| Short term investments | ||||
| Net receivables | $0.38 | $0.19 | $0.79 | $0.75 |
| Inventory | ||||
| Total current assets | $5.22 | $4.62 | $4.74 | $9.63 |
| Long term investments | ||||
| Property, plant & equipment | $0.19 | $0.21 | $0.23 | $0.25 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.69 | $0.71 | $0.69 | $0.4 |
| Total investments | ||||
| Total assets | $5.91 | $5.34 | $5.43 | $10.03 |
| Current liabilities | ||||
| Accounts payable | $1.75 | $1.66 | $2.2 | $3.02 |
| Deferred revenue | $0.02 | $0.06 | ||
| Short long term debt | $0.08 | $0.08 | $0.07 | $0.07 |
| Total current liabilities | $2.76 | $2.65 | $5.52 | $6.47 |
| Long term debt | $0.09 | $0.11 | $0.13 | $0.15 |
| Total noncurrent liabilities | $0.09 | $0.11 | $0.13 | $0.15 |
| Total debt | $0.17 | $0.19 | $0.2 | $0.22 |
| Total liabilities | $2.86 | $2.77 | $5.66 | $6.62 |
| Shareholders' equity | ||||
| Retained earnings | -$111.05 | -$111.41 | -$110.24 | -$106.57 |
| Other shareholder equity | ||||
| Total shareholder equity | $3.05 | $2.57 | -$0.23 | $3.42 |
| (in millions $) | 31 Dec 2023 | 30 Oct 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.27 | $3.05 | $27.62 | $7.35 |
| Short term investments | ||||
| Net receivables | $0.79 | |||
| Inventory | ||||
| Total current assets | $4.74 | $5.41 | $28.81 | $7.64 |
| Long term investments | ||||
| Property, plant & equipment | $0.23 | $0.3 | $0.18 | $0.27 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.69 | $0.42 | $0.18 | $0.36 |
| Total investments | ||||
| Total assets | $5.43 | $5.83 | $28.99 | $7.99 |
| Current liabilities | ||||
| Accounts payable | $2.2 | $4.75 | $3.78 | $2.06 |
| Deferred revenue | $0.02 | $0.17 | $0.52 | $0.5 |
| Short long term debt | $0.07 | $0.05 | $0.1 | $0.1 |
| Total current liabilities | $5.52 | $8.16 | $6.7 | $4.72 |
| Long term debt | $0.13 | $0.2 | $0.03 | $0.25 |
| Total noncurrent liabilities | $0.13 | $0.2 | $0.03 | $0.25 |
| Total debt | $0.2 | $0.26 | $0.13 | $0.35 |
| Total liabilities | $5.66 | $8.37 | $6.73 | $4.97 |
| Shareholders' equity | ||||
| Retained earnings | -$110.24 | -$91.41 | -$61.69 | -$36.71 |
| Other shareholder equity | ||||
| Total shareholder equity | -$0.23 | -$2.54 | $22.26 | $3.02 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.02 | $0.04 | $0.04 | |
| Cost of revenue | ||||
| Gross Profit | $0.02 | $0.04 | $0.04 | |
| Operating activities | ||||
| Research & development | $2.17 | $0.64 | $1.84 | $2.41 |
| Selling, general & administrative | $1.7 | $0.65 | $1.79 | $1.54 |
| Total operating expenses | $3.87 | $1.3 | $3.64 | $3.95 |
| Operating income | -$3.87 | -$1.28 | -$3.6 | -$3.92 |
| Income from continuing operations | ||||
| EBIT | $0.37 | -$1.17 | -$3.68 | -$3.95 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | $0.37 | -$1.17 | -$3.68 | -$3.95 |
| Income (for common shares) | $0.37 | -$1.17 | -$3.68 | -$3.95 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.15 | $0.35 | $0.48 | |
| Cost of revenue | ||||
| Gross Profit | $0.15 | $0.35 | $0.48 | |
| Operating activities | ||||
| Research & development | $11.81 | $21.44 | $16.63 | $9.88 |
| Selling, general & administrative | $7.13 | $8.58 | $8.94 | $7.53 |
| Total operating expenses | $18.94 | $30.02 | $25.57 | $24.24 |
| Operating income | -$18.79 | -$29.67 | -$25.09 | -$24.24 |
| Income from continuing operations | ||||
| EBIT | -$18.83 | -$29.72 | -$24.98 | -$24.29 |
| Income tax expense | ||||
| Interest expense | -$0.02 | |||
| Net income | ||||
| Net income | -$18.83 | -$29.72 | -$24.98 | -$24.27 |
| Income (for common shares) | -$18.83 | -$29.72 | -$24.98 | -$65.6 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Net income | $0.37 | -$1.17 | -$3.68 | -$3.95 |
| Operating activities | ||||
| Depreciation | $0.02 | $0.02 | $0.02 | $0.02 |
| Business acquisitions & disposals | -$0.44 | |||
| Stock-based compensation | $0.06 | $0.05 | $0.05 | $0.05 |
| Total cash flows from operations | $0.72 | -$3.09 | -$4.56 | -$6.17 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.17 | -$0.01 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.06 | $3.84 | -$0.02 | $1.82 |
| Net borrowings | -$0 | |||
| Total cash flows from financing | $0.04 | $3.84 | -$0.02 | $1.81 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $0.76 | $0.75 | -$4.75 | -$4.37 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$18.83 | -$29.72 | -$24.98 | -$24.27 |
| Operating activities | ||||
| Depreciation | $0.08 | $0.09 | $0.1 | $0.06 |
| Business acquisitions & disposals | -$0.44 | -$0.9 | ||
| Stock-based compensation | $0.25 | $0.88 | $1.38 | $0.37 |
| Total cash flows from operations | -$21.34 | -$27.69 | -$22.55 | -$15.61 |
| Investing activities | ||||
| Capital expenditures | -$0 | -$0.08 | ||
| Investments | ||||
| Total cash flows from investing | -$0.44 | -$0.9 | -$0 | -$0.08 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $21.01 | $1.84 | $42.85 | $19.07 |
| Net borrowings | -$0 | -$0.02 | $0.13 | |
| Total cash flows from financing | $21.01 | $4.01 | $42.83 | $23.01 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$0.78 | -$24.57 | $20.27 | $7.31 |
News
Fundamentals
| Market cap | $2.65M |
|---|---|
| Enterprise value | -$971.70K |
| Shares outstanding | 3.11M |
| Revenue | $92.73K |
|---|---|
| EBITDA | -$8.35M |
| EBIT | -$8.43M |
| Net Income | -$8.43M |
| Revenue Q/Q | -100.00% |
| Revenue Y/Y | -53.29% |
| P/E ratio | -0.31 |
|---|---|
| EV/Sales | -10.48 |
| EV/EBITDA | 0.12 |
| EV/EBIT | 0.12 |
| P/S ratio | 28.53 |
| P/B ratio | 0.87 |
| Book/Share | 0.98 |
| Cash/Share | 1.22 |
| EPS | -$2.71 |
|---|---|
| ROA | -126.19% |
| ROE | -382.19% |
| Debt/Equity | -25.03 |
|---|---|
| Net debt/EBITDA | 0.11 |
| Current ratio | 1.89 |
| Quick ratio | 1.89 |